Biocompatibles puts shareholder issues behind it as it embarks on operational future in interventional radiology
This article was originally published in Clinica
Executive Summary
Biocompatibles International CEO Crispin Simon has only one regret about this year's disposal of the cardiovascular stent business to Abbott, he told Clinica